Special Issue "Dengue Vaccines"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 May 2015) | Viewed by 6232
Special Issue Editors
Interests: dengue virology and pathogenesis; flavivirus-host interactions; development of molecular correlates of vaccine and antiviral safety and efficacy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Dengue vaccine development has come a long way, but we are not there yet. The recently released results of the multi-centre Phase 3 efficacy trial in Asia for the live-attenuated, recombinant dengue fever vaccine (chimeric, with the 17D yellow fever virus as the backbone) have yet again shown that an optimal dengue vaccine remains a scientific challenge. The successful rollout of a vaccine that induces high levels of tetravalent protection may hinge on detailed understanding of dengue pathogenesis and immunity. Addressing the gaps in knowledge in these fields must thus be our top priority.
Immense progress has been made in the field of dengue virology and immunology in the past decade. The present issue on “Untangling the Complexity of Dengue Vaccine Development” will bring together primary data on clinical, virological, and immunological studies. Up-to-date summaries of pre-clinical and phase 1–3 trials will provide an indication of the current status of dengue vaccine development. Lastly, this issue will also include articles that address the economics and policies related to dengue vaccine introduction. We envisage that this Special Issue will serve as both an information resource as well as a timely alignment between primary research efforts and vaccine development strategies.
Prof. Dr. Annelies Wilder-Smith
Prof. Dr. Eng Eong Ooi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- dengue
- live attenuated dengue vaccines
- new generation dengue vaccines
- inactivated dengue vaccines
- immune correlate
- human controlled infections
- vaccine efficacy
- antibody dependent immune enhancement
- cellular immunity